Quality of Life in Patients With a Major Mental Disorder in Singapore

Choo, Carol C; Chew, Peter K. H.; Ho, Cyrus S.H.; Ho, Roger

doi:10.3389/fpsyt.2018.00727

Cited by 32 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lifetime prevalence of major depressive disorder was 5.8% [92]. Disorder severity negatively predicted mental health component of health-related quality of life (HRQOL) for Singaporeans suffering from depression [9]. Among Singaporean psychiatric outpatients with depression and anxiety disorders, 43.6% experienced moderate to high levels of self-stigma [93].…”

Section: Stigma Related To Psychiatric Illnesses and Advancement Of Amentioning

confidence: 99%

See 1 more Smart Citation

Overview of Stigma against Psychiatric Illnesses and Advancements of Anti-Stigma Activities in Six Asian Societies

Zhang

Sun

Jatchavala

et al. 2019

IJERPH

157

View full text Add to dashboard Cite

Background: In psychiatry, stigma is an attitude of disapproval towards people with mental illnesses. Psychiatric disorders are common in Asia but some Asians receive inadequate treatment. Previous review found that Asians with mental illness were perceived to be dangerous and aggressive. There is a need for renewed efforts to understand stigma and strategies which can effectively reduce stigma in specific Asian societies. The objective of this systematic review was to provide an up-to-date overview of existing research and status on stigma experienced by psychiatric patients and anti-stigma campaigns in China, Hong Kong, Japan, Singapore, Korea, and Thailand. Methods: A systematic literature search was conducted in the following databases, including PubMed, PsycINFO, Embase, Web of Science, and local databases. Studies published in English and the official language of included countries/territories were considered for inclusion in the systematic review. Any article on stigma related to any form of psychiatric illness in the six Asian societies was included. Results: One hundred and twenty-three articles were included for this systematic review. This review has six major findings. Firstly, Asians with mental illnesses were considered as dangerous and aggressive, especially patients suffering from schizophrenia and bipolar disorder; second, psychiatric illnesses in Asian societies were less socially-acceptable and were viewed as being personal weaknesses; third, stigma experienced by family members was pervasive and this is known as family stigma; fourth, this systemic review reported more initiatives to handle stigma in Asian societies than a decade ago; fifth, there have been initiatives to treat psychiatric patients in the community; and sixth, the role of supernatural and religious approaches to psychiatric illness was not prevailing. Conclusion: This systematic review provides an overview of the available scientific evidence that points to areas of needed intervention to reduce and ultimately eliminate inequities in mental health in Asia.

show abstract

Section: Stigma Related To Psychiatric Illnesses and Advancement Of Amentioning

confidence: 99%

“…Discrimination against people diagnosed with psychiatric illnesses may lead to delays and avoidance of psychiatric treatments [7]. Stigma and discrimination are the most significant challenges that people living with chronic diseases face, leading to a negative quality of life [8,9].…”

Section: Introductionmentioning

confidence: 99%

Overview of Stigma against Psychiatric Illnesses and Advancements of Anti-Stigma Activities in Six Asian Societies

Zhang

Sun

Jatchavala

et al. 2019

IJERPH

157

View full text Add to dashboard Cite

show abstract

“…Quality of life (QOL) refers to individuals' subjective perception of their own life status, which involves the domains of physical health, psychological state, social relations and living conditions (1). In the past decade, QOL has been paid more and more attention by psychiatrists because of its importance for outcomes of patients with mental illness (2)(3)(4), especially for schizophrenia (5,6), major depression (7,8) and bipolar disorder (9,10). In fact, QOL is not one of the traditional or formal measures of outcomes.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life in Patients With Methamphetamine Use Disorder: Relationship to Impulsivity and Drug Use Characteristics

et al. 2020

View full text Add to dashboard Cite

Background: The quality of life (QOL) of patients with methamphetamine use disorder (MAUD) is increasingly recognized as an important outcome. Previous studies have found that impulsivity is negatively associated with QOL in mental disorders, but this relationship is rarely confirmed in patients with MAUD. We hypothesized that impulsivity is negatively correlated with QOL in patients with MAUD based on previous findings. In addition, a variety of drug use characteristics of patients that may potentially affect their QOL need to be further explored. Therefore, the purpose of this study was to explore the relationship between impulsivity, multiple drug use characteristics, and QOL in patients with MAUD. Methods: A total of 379 patients with MAUD were recruited, and the majority of them were male (85.5%), with an average age of 33.93 ± 7.08 years. Two psychiatrists conducted semi-structured interviews with methamphetamine (MA) users in two compulsory drug rehabilitation centers to obtain their demographics and drug use characteristics. The Barratt Impulsiveness Scale-11 (BIS-11) and Brief WHO Quality of Life Assessment (WHOQOL-BREF) were used to assess patients' impulsivity and QOL, respectively. Correlation and univariate regression analysis were used to explore the relationships between impulsivity, a series of drug use characteristics and patients' QOL in different domains. Further multiple linear regression analysis was used to identify what extent the above clinical variables explained the variations in patients' QOL. Results: Age, marital status, employment, and various drug use characteristics were significantly associated with at least one QOL domain. Among them, married and full-time job were positively correlated with QOL, while others were negatively correlated with QOL. The total score of BIS-11 was significantly negatively correlated with all four domains of QOL. Impulsivity, a range of drug use characteristics and certain

show abstract

“…Further, both these reviews only provided an assessment of efficacy and safety outcomes, and did not include important outcomes of patient-focused assessments, such as assessment of functional impairment and QoL. Currently, there is growing interest in assessing the QoL and functional status impairment in patients with psychological disorders 21 22. In addition, the importance of including such assessments in evaluations of the influence of psychological disorders and their treatment is widely recognised 23–26.…”

Section: Introductionmentioning

confidence: 99%

Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes

et al. 2019

View full text Add to dashboard Cite

ObjectivesThe aim of this study was to investigate the efficacy, tolerability, safety, and impact on quality of life (QoL) and functional status of vortioxetine treatment for patients with generalised anxiety disorder (GAD) by performing a meta-analysis of randomised controlled trials (RCTs).DesignSystematic review and meta-analysis.Data sourcesData mining was conducted in January 2019 across PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials Cochrane Library, Web of science and ClinicalTrials.gov.Eligibility criteria for selecting studiesAll published RCTs, which assessed the effect of vortioxetine treatment for patients with GAD when compared with a placebo group, were included.Data extraction and synthesisRelevant data were extracted and synthesised narratively. Results were expressed as standardised mean differences or ORs with 95% CIs.ResultsOur meta-analysis showed that multiple doses (2.5, 5 and 10 mg/day) of vortioxetine did not significantly improve the response rates, compared with placebo (OR 1.16, 95% CI 0.84 to 1.60, p=0.38; OR 1.41, 95% CI 0.82 to 2.41, p=0.21; and OR 1.05, 95% CI 0.76 to 1.46, p=0.75). Moreover, there was no statistically significant difference regarding the remission rates, discontinuation for any reason rates, discontinuation due to adverse events rates, Short-Form 36 Health Survey scores or Sheehan Disability Scale scores between administration of multiple doses (2.5, 5 and 10 mg/day) of vortioxetine and placebo.ConclusionsAlthough our results suggest that vortioxetine did not improve the GAD symptoms, QoL and functional status impairment of patients with GAD, it was safe and well tolerated. Clinicians should interpret and translate our data with caution, as the meta-analysis was based on a limited number of RCTs.

show abstract

Quality of Life in Patients With a Major Mental Disorder in Singapore

Cited by 32 publications

References 50 publications

Overview of Stigma against Psychiatric Illnesses and Advancements of Anti-Stigma Activities in Six Asian Societies

Overview of Stigma against Psychiatric Illnesses and Advancements of Anti-Stigma Activities in Six Asian Societies

Quality of Life in Patients With Methamphetamine Use Disorder: Relationship to Impulsivity and Drug Use Characteristics

Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes

Contact Info

Product

Resources

About